Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCD Regimen for Newly Diagnosed POEMS Syndrome
NCT07652879Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in POEMS syndrome (POEMS), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Overall Hematological Response Rate at 2 years, Overall VEGF Response Rate at 2 years and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
carfilzomib
03
Conditions
POEMS syndrome (POEMS)
Beyond the preview
Go deeper on NCT07652879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652879.